Clinical Trials
28 trialsNCT06308263 2026-04-23
Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT05054725 2026-01-06
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Phase 2 Completed
NCT04480814 2025-12-30
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC
Pharmassist Ltd
Completed
NCT04997902 2025-12-23
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
Phase 1/2 Completed
NCT04564027 2025-08-29
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
AstraZeneca
Phase 2 Completed
NCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed
NCT04774952 2025-04-15
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
Revolution Medicines, Inc.
Phase 1 Completed
NCT03126019 2025-03-14
CITADEL-203
Incyte Corporation
Phase 2 Completed
NCT03309150 2024-11-29
ATRi Transition Rollover Study
Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT05246111 2024-11-22
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Phase 1 Completed
NCT04768296 2024-09-26
Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)
EMD Serono
Phase 2 Completed
NCT03439046 2024-08-01
BioItaLEE
Novartis
Phase 3 Completed
NCT04095273 2024-04-02
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
Bayer
Phase 1 Completed
NCT01320085 2024-01-24
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
Pfizer
Phase 2 Completed
NCT05982886 2023-08-09
Biomarker Testing and Treatment Patterns Among Patients With PIK3CA Mutation in Advanced Breast Cancer
Novartis
Completed
NCT03730142 2023-04-18
A Study of WXFL10030390 in Patients With Advanced Solid Tumors or Lymphoma
Shanghai Jiatan Pharmatech Co., Ltd
Phase 1 Completed
NCT04285723 2023-02-09
EPIK-P1
Novartis
Completed
NCT02684032 2022-07-27
A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
Celcuity Inc
Phase 1 Completed
NCT04425200 2021-12-07
ZENSHIN
AstraZeneca
Completed
NCT00600275 2020-12-17
A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
Novartis
Phase 1/2 Completed
NCT00726583 2018-05-17
Phase I Trial of Oral PX-866
Seagen Inc.
Phase 1 Completed
NCT01204099 2018-05-16
Study of PX-866 and Docetaxel in Solid Tumors
Seagen Inc.
Phase 1/2 Completed
NCT01252628 2018-05-16
Phase 1 and 2 Study of PX-866 and Cetuximab
Seagen Inc.
Phase 1/2 Completed
NCT01449370 2017-03-09
Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer
Takeda
Phase 1 Completed
NCT01572727 2017-03-09
BELLE-4
Novartis
Phase 2/3 Completed
NCT00790400 2017-02-17
EXIST-2
Novartis
Phase 3 Completed
NCT02598570 2017-02-06
Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma
AbbVie
Phase 1 Completed